Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Mark L. Greenlee is active.

Publication


Featured researches published by Mark L. Greenlee.


Bioorganic & Medicinal Chemistry Letters | 1999

Synthesis and SAR of thioester and thiol inhibitors of IMP-1 Metallo-β-Lactamase

Mark L. Greenlee; Joanne B. Laub; James M. Balkovec; Milton L. Hammond; Gail G. Hammond; David L. Pompliano; Jeffrey H. Epstein-Toney

Potent thioester and thiol inhibitors of IMP-1 metallo-β-lactamase have been synthesized employing a solid-phase Mitsunobu reaction as the key step.


Bioorganic & Medicinal Chemistry Letters | 1999

Dicationic 2-fluorenonylcarbapenems: Potent anti-MRS agents with improved solubility and pharmacokinetic properties

Mark L. Greenlee; Joanne B. Laub; Gregory P. Rouen; Frank P. DiNinno; Milton L. Hammond; Joann Huber; Jon G. Sundelof; Gail G. Hammond

The synthesis and biological evaluation of a series of dicationic-substituted 2-fluorenonylcarbapenems is described. This class of compounds showed enhanced water solubility while maintaining potent activity against MRS. Introduction of a 1-beta-methyl substituent was found to improve pharmacokinetics.


Tetrahedron Letters | 1990

A highly efficient method for the preparation of 2-aryl substituted carbapenems exploiting a Pd(0) mediated cross-coupling reaction

Thomas A. Rano; Mark L. Greenlee; Frank P. DiNinno

Abstract A remarkably mild procedure for the synthesis of 2-aryl substituted carbapenems via a palladium catalyzed coupling reaction of a vinyl triflate with aryl stannanes is described. Employing Pd2(DBA)3.CHCl3 as the catalyst and tris(2,4,6-trimethoxyphenyl)phosphine as the ligand provides generous yields of the desired β-lactams. Reaction times are brief while reaction temperatures never exceed ambient.


The Journal of Steroid Biochemistry and Molecular Biology | 2004

Selective glucocorticoid receptor nonsteroidal ligands completely antagonize the dexamethasone mediated induction of enzymes involved in gluconeogenesis and glutamine metabolism.

Monica Einstein; Mark L. Greenlee; Greg Rouen; Ayesha Sitlani; Joe Santoro; Chuanlin Wang; Shilpa Pandit; Paul Mazur; Isabella Smalera; Alehna P. M. Weaver; Ying Ying Zeng; Lan Ge; Theresa M. Kelly; Tony Paiva; Wayne M. Geissler; Ralph T. Mosley; Joanne M. Williamson; Amjad Ali; Jim Balkovec; Georgianna Harris

Glucocorticoids (GCs) are vital multi-faceted hormones with recognized effects on carbohydrate, protein and lipid metabolism. Previous studies with the steroid antagonist, RU486 have underscored the essential role of GCs in the regulation of these metabolic pathways. This article describes the discovery and characterization of novel GRalpha selective nonsteroidal antagonists (NSGCAs). NSGCAs 2 and 3 are spirocyclic dihydropyridine derivatives that selectively bind the GRalpha with IC(50s) of 2 and 1.5 nM, respectively. Importantly, these compounds are full antagonists of the induction by dexamethasone (Dex) of marker genes for glucose and glutamine metabolism; the tyrosine amino transferase (TAT) and glutamine synthetase (GS) enzymes, respectively. In contrast, GC-dependent transcriptional repression of the collagenase 1 (MMP-1) enzyme, an established GRalpha responsive proinflammatory gene; is poorly antagonized by these compounds. These NSGCAs might have useful applications as tools in metabolic research and drug discovery.


Bioorganic & Medicinal Chemistry Letters | 2012

Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase.

Brian Heasley; Gregory J. Pacofsky; Ahmed Mamai; Hao Liu; Kingsley Nelson; Ghjuvanni Coti; Michael Robert Peel; James M. Balkovec; Mark L. Greenlee; Paul A. Liberator; Dongfang Meng; Dann L. Parker; Robert R. Wilkening; James M. Apgar; Fred Racine; Ming Jo Hsu; Robert A. Giacobbe; Jennifer Nielsen Kahn

Orally bioavailable inhibitors of β-(1,3)-D-glucan synthase have been pursued as new, broad-spectrum fungicidal therapies suitable for treatment in immunocompromised patients. Toward this end, a collaborative medicinal chemistry program was established based on semisynthetic derivatization of the triterpenoid glycoside natural product enfumafungin in order to optimize in vivo antifungal activity and oral absorption properties. In the course of these studies, it was hypothesized that the pharmacokinetic properties of the semisynthetic enfumafungin analog 3 could be improved by tethering the alkyl groups proximal to the basic nitrogen of the C3-aminoether side chain into an azacyclic system, so as to preclude oxidative N-demethylation. The results of this research effort are disclosed herein.


Bioorganic & Medicinal Chemistry Letters | 1999

2-Naphthylcarbapenems: Broad spectrum antibiotics with enhanced potency against MRSA

Mark L. Greenlee; Frank P. DiNinno; Jeffrey J. Herrmann; Cynthia Jaworsky; David A. Muthard; Thomas N. Salzmann

A regioisomeric set of 2-naphthylcarbapenems featuring cationic substituents was synthesized. Optimal placement of the cationic group was found to markedly improve activity against methicillin-resistant staphylococci while maintaining a good spectrum of gram-negative activity.


Bioorganic & Medicinal Chemistry | 2008

Discovery of betamethasone 17α-carbamates as dissociated glucocorticoid receptor modulators in the rat

Amjad Ali; James M. Balkovec; Mark L. Greenlee; Milton L. Hammond; Greg Rouen; Gayle E. Taylor; Monica Einstein; Lan Ge; Georgianna Harris; Terri M. Kelly; Paul Mazur; Shilpa Pandit; Joseph C. Santoro; Ayesha Sitlani; Chuanlin Wang; Joann Williamson; Michael J. Forrest; Ester Carballo-Jane; Silvi Luell; Karen Lowitz; Denise M. Visco

A series of betamethasone 17alpha-carbamates were designed, synthesized, and evaluated for their ability to dissociate the two main functions of the glucocorticoid receptor, that is, transactivation and transrepression, in rat cell lines. A number of alkyl substituted betamethasone 17alpha-carbamates were identified with excellent affinity for the glucocorticoid receptor (e.g., 7, GR IC(50) 5.1 nM) and indicated dissociated profiles in functional assays of transactivation (rat tyrosine aminotransferase, TAT, and rat glutamine synthetase, GS) and transrepression (human A549 cells, MMP-1 assay). Gratifyingly, the in-vivo profile of these compounds, for example, 7, also indicated potent anti-inflammatory activity with impaired effects on glucose, insulin, triglycerides, and body weight. Taken together, these results indicate that dissociated glucocorticoid receptor modulators can be identified in rodents.


Bioorganic & Medicinal Chemistry Letters | 1999

The synthesis and anti-MRSA activity of amidinium-substituted 2-dibenzofuranylcarbapenems.

Joanne B. Laub; Mark L. Greenlee; Frank P. DiNinno; Joann Huber; Jon G. Sundelof

A series of amidinium-substituted 2-dibenzofuranylcarbapenems with potent activity against MRSA has been synthesized via a Stille cross-coupling reaction. These new carbapenems show reduced serum protein binding and improved in vivo efficacy as a consequence of the positively charged amidinium substituent.


Organic Letters | 2008

Use of fluoroalkyl as a latent group for internal alkylation: application to the synthesis of bridged tetrahydrofluorenones.

Dann L. Parker; Amy K. Fried; Dongfang Meng; Mark L. Greenlee

Tetrahydrofluorenones which possess a C9a-fluoroalkyl substituent were efficiently converted to tetrahydrofluorenones which contain a ring bridging C9a-C2. Conditions include a stepwise sequence of conversion to an alkyl bromide followed by treatment with base, and a direct cyclization by treatment with lithium chloride in DMF heated to 150 degrees C.


Bioorganic & Medicinal Chemistry Letters | 2015

Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin.

James M. Apgar; Robert R. Wilkening; Mark L. Greenlee; James M. Balkovec; Amy M. Flattery; George K. Abruzzo; Andrew Galgoci; Robert A. Giacobbe; Charles Gill; Ming Jo Hsu; Paul A. Liberator; Andrew S. Misura; Mary Motyl; Jennifer Nielsen Kahn; Maryann Powles; Fred Racine; Jasminka Dragovic; Bahanu Habulihaz; Weiming Fan; Robin Kirwan; Shu Lee; Hao Liu; Ahmed Mamai; Kingsley Nelson; Michael Robert Peel

The clinical success of the echinocandins, which can only be administered parentally, has validated β-1,3-glucan synthase (GS) as an antifungal target. Semi-synthetic modification of enfumafungin, a triterpene glycoside natural product, was performed with the aim of producing a new class of orally active GS inhibitors. Replacement of the C2 acetoxy moiety with various heterocycles did not improve GS or antifungal potency. However, replacement of the C3 glycoside with an aminoether moiety dramatically improved oral pharmacokinetic (PK) properties while maintaining GS and antifungal potency. Installing an aminotetrazole at C2 in conjunction with an N-alkylated aminoether at C3 produced derivatives with significantly improved GS and antifungal potency that exhibited robust oral efficacy in a murine model of disseminated candidiasis.

Researchain Logo
Decentralizing Knowledge